Illuminating Acromegaly: Lab Data Can Change HCP Engagement
Acromegaly, a rare hormonal disorder caused by excess growth hormone (GH) production, often goes...
Rapidly Identifying HCPs Treating AML: The Lab Data Advantage
Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow,...
Unlocking Precision Targeting in Lysosomal Storage Disorders: How Prognos Health Empowers Commercial Teams
Lysosomal Storage Disorders (LSDs) present a unique challenge for pharmaceutical and biotech...
Decoding the Complexities of Breast Cancer Treatment: The Role of Lab Data & HCP Engagement
Breast cancer treatment is an intricate field, with ongoing research and development leading to...
Optimizing HCP Engagement: The Power of Timely, Precise, and Actionable Patient Alerts
Effective HCP engagement is a cornerstone of successful pharmaceutical marketing. The right...
Rare Disease Pharma: Navigating the DOJ's Sponsored Testing Ruling
The Department of Justice (DOJ) recently made waves in the pharmaceutical industry with a ruling...
Unveiling New Insights in NSCLC with Large-Scale FISH Panel Data
The landscape of Non-Small Cell Lung Cancer (NSCLC) treatment is constantly evolving, with...
Liquid Biopsies: A Game-Changer for Outreach to Healthcare Providers
In the fast-paced world of medicine, staying ahead of the curve is essential for pharmaceutical...
A shift to patient-first at Digital Pharma East
Like many life sciences marketing professionals in the life sciences and pharma industry, I...
.png)
Brand Eligible Patient Alerts Supercharge Marketing & Sales Execution
Q: What are alerts? Why are pharma brand teams using brand eligible patient alerts as part of...